ClinicalTrials.gg
RecruitingNCT07052045GET-FASTUpdated Jan 20, 2026

One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy

An interventional study of One Stop Management and Usual care management in Stroke Acute, Acute Ischemic Stroke AIS and Hemorrhagic Stroke, Intracerebral, sponsored by Prof. Dr. Jan Liman. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Primary conditionHemorrhagic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hemorrhagic Stroke
Why
  1. The study's listed conditions name Hemorrhagic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Prof. Dr. Jan Liman · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hemorrhagic Stroke with a site in Germany — 3 open to participants now, 5 under way, none of them phase 3. Hemorrhagic Stroke · Germany.

Planned enrollment
5th of 11
390 · median 380
Started
2025
the only one that year
No phase
5 of 14
2 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Prof. Dr. Jan Liman

Among the 14 studies in Hemorrhagic Stroke with a site in Germany, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 5 with no phase, and was the 14th registered.

Hemorrhagic Stroke

234 studies on the registry are indexed under Hemorrhagic Stroke; 94 are open to participants now.

Browse Hemorrhagic Stroke studies →

Open to participants now

3 of the 14 studies in Hemorrhagic Stroke with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 62 Hemorrhagic Stroke studies recruiting now, 36 (58%) set no upper age limit and 7 (11%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hemorrhagic Stroke with a site in Germany, or all of them as a file.
02

Study summary

Stroke, especially acute ischemic stroke (AIS) caused by a blocked blood vessel in the brain, is a leading cause of death and long-term disability. When the blockage is in a large blood vessel, a procedure called endovascular therapy (EVT)-where the clot is removed using a catheter-is highly effective. However, the sooner EVT is done, the better the outcome for the patient.

Research has shown that delays between arriving at the hospital and starting EVT (called door-to-groin time) significantly reduce the chances of recovery. For example, reducing this time by just 15 minutes can mean 20 more patients (out of 1,000 treated) going home instead of to a care facility. Even a 10-minute improvement can result in over 100 extra days of independent living for patients and save more than $10,000 in healthcare costs per patient.

To reduce these delays, hospitals have improved stroke workflows. In the current standard approach, patients suspected of having a stroke are taken first to a CT scan room to confirm the diagnosis, and then, if a treatable occlusion is found, to a separate room for EVT. This usually takes around 60-70 minutes.

However, moving patients between rooms takes time. A new approach called "One-Stop management" could solve this. In this method, both the brain scan and the EVT procedure are done in one room-the angiography suite-using special imaging tools called flat panel CT (FDCT) and FDCT angiography (FDCT-A).

A previous study with 230 patients showed that One-Stop management is possible and saves time. But there's a challenge: the decision to follow the One-Stop pathway is made before a clear diagnosis is available. That's important because not all strokes benefit from EVT. Severe stroke symptoms (measured by a score called NIHSS ≥10) can come from:

  • A large or medium vessel blockage (which EVT can treat),
  • A small vessel blockage, or
  • A bleed in the brain (hemorrhage). Only the first group benefits from EVT. About 85% of patients with severe symptoms fall into this category. The rest-about 15%-would not benefit, and there are concerns that FDCT might be slightly less accurate than regular CT in diagnosing these types of strokes. So, we need to test whether One-Stop management is safe and effective for all patients, not just those with treatable blockages.

To do this, the GET-FAST trial will compare the One-Stop approach to the standard two-room process. Patients will be randomly assigned to one of the two strategies. Importantly, this randomization won't affect their actual treatment-everyone will still receive the best care according to current medical guidelines. The main endpoint for the evaluation of the One-Stop approach will be long-term (at 90 days) disability and dependency in daily life as measured with the modified Rankin Scale (mRS).

This study will include all patients as they were assigned, regardless of what type of stroke they actually had. This is called an "intention-to-treat" analysis, and it provides the most reliable measure of the overall impact of One-Stop management.

Another key aspect of the trial is that any CE-certified imaging system already used in hospitals can be used for the One-Stop process-no specific brand or model is required. This makes the results more applicable to real-world hospital settings.

If GET-FAST proves that One-Stop management leads to better patient outcomes, this could transform how stroke care is delivered. More patients could return to independent living, and fewer would require long-term care -leading to major reductions in healthcare costs. For example, even a one-point improvement on a common stroke disability scale (mRS) can triple the savings in lifetime care costs.

03

Conditions studied

  • Stroke Acute
  • Acute Ischemic Stroke AIS
  • Hemorrhagic Stroke, Intracerebral

Browse trials for

04

In context

Hemorrhagic Stroke Reclassified

234 studies on the registry are indexed under Hemorrhagic Stroke; 94 are open to participants now.

This study's planned enrollment of 390 is above the median of 58 across 156 interventional studies indexed under Hemorrhagic Stroke.

Browse Hemorrhagic Stroke studies →

Lead sponsor

This is the only study on the registry with Prof. Dr. Jan Liman as lead sponsor.

Compared within Hemorrhagic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptoms suggestive of an acute ischemic stroke caused by a large or medium vessel occlusion as defined by a National Institute of Health Stroke Scale (NIHSS) Score of ≥ 10 points
  • Patient presents directly to the treating hospital (mothership patient) within 4.5 hours of last seen well (LSW)
  • Age ≥ 18 years
  • Patient was independent in daily activities prior to the stroke (pre stroke modified Rankin Scale of 0 - 2)
  • Endovascular treatment team available (Neurologist, Interventionist, Anesthesiologist, Nursery, Technicians)
  • as documented by signature or fulfilling the criteria for emergency consent procedures

Exclusion criteria

Exclusion Criteria:

  • Severe comorbidities, which will likely prevent improvement or follow-up
  • In-hospital stroke
  • Clinical symptoms suggestive of intracranial hemorrhage (deterioration of patient during transport, vomiting or depressed consciousness)
  • Strong suspicion of functional neurological symptom disorder / conversion disorder
  • Hemodynamically unstable patients who require advanced vital support
  • Angiography room occupied by other procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    One Stop Management

    Patients within the intervention group will be transported directly after randomization to the angiography room.

    Other: One Stop Management

  • Active comparator
    Usual Care Management

    Patients within the control group will be transported directly after randomization to the multidetector CT (MDCT) room for diagnostic imaging with non-contrast MDCT and MDCT-A.

    Other: Usual care management

Interventions

  • OtherOne Stop Management

    Patients within the intervention group will be transported directly after randomization to the angiography room. In the angiography room diagnostic imaging will be performed using cranial non-contrast FDCT and FDCT-A with subsequent EVT (if a treatable vessel occlusion was identified). Therefore, diagnostics and treatment will be performed in the same room (One-Stop management). Only patients with a treatable occlusion will undergo arterial puncture.

  • OtherUsual care management

    Patients within the control group will be transported directly after randomization to the multidetector CT (MDCT) room for diagnostic imaging with non-contrast MDCT and MDCT-A. IVT will be given directly in the MDCT room if no contraindication is present. If on diagnostic imaging a treatable vessel occlusion was identified, the patient will be transported to the angiography room, where EVT will be performed.

07

What researchers measure

Primary outcomes

  1. Degree of Dependency and disability in daily activities

    As assessed with the modified Rankin Scale (mRS); The mRS runs from 0-6, running from perfect health without symptoms (0) to death (6).

    Time frame: 90 days (+/- 15 days) after randomization

Secondary outcomes

  1. Early neurological improvement

    Early neurological improvement is defined as a decrease of at least 4 points on the National Institute of Health Stoke Scale (NIHSS) compared to baseline; range of NIHSS 0 - 42 with higher values indicating more severe neurological deficit

    Time frame: 5 - 7 days after randomization or discharge if earlier

  2. Early neurological deterioration

    Early neurological deterioration is defined as an increase of at least 4 points on National Institutes of Health Stroke Scale compared to baseline, death or persistent coma; range of NIHSS 0 - 42 with higher values indicating more severe neurological deficit

    Time frame: 5 - 7 days after randomization or discharge if earlier

  3. Independent functional outcome

    Defined as a modified Rankin Scale of 0 to 2 (mRS); The mRS runs from 0-6, running from perfect health without symptoms (0) to death (6).

    Time frame: 90 days (+ / - 15 days) after randomization

  4. Cognitive function

    As assessed with the Montreal Cognitive Assessment Test (MoCA); range 0 - 30 with lower values indicating more severe cognitive impairment

    Time frame: 90 days (+/- 15 days) after randomization

  5. Health-related quality of life

    As assessed with the Euro-Qol 5d; 5 point scale with higher values indicating better quality of life in the specific domain

    Time frame: 90 days (+/- 15 days) after randomization

  6. Degree of Dependency and disability in daily activities

    As assessed with the modified Rankin Scale (mRS); The mRS runs from 0-6, running from perfect health without symptoms (0) to death (6).

    Time frame: 365 days (+/- 30 days) after randomization

  7. Health-related quality of life

    As assessed with the Euro-QoL-5D; 5 point scale with higher values indicating better quality of life in the specific domain

    Time frame: 365 days (+/- 30 days) after randomization

  8. Cognitive function

    As assessed with the telephone Montreal Cognitive Assessment Test (T-MoCA); range 0 - 22 with lower values indicating more severe cognitive impairment

    Time frame: 365 days (+/- 30 days) after randomization

Other outcomes

  1. Safety: Symptomatic intracranial hemorrhage

    All intracerebral hemorrhages will be classified by the blinded Core Lab according to the Heidelberg Bleeding Classification. Symptomatic intracerebral hemorrhage (sICH) will be defined using a modified SITS-MOST definition: sICH is defined as the presence of a parenchymal hemorrhage type 2 (local or remote), subarachnoid hemorrhage, and/or intraventricular hemorrhage on imaging performed 24 hours post-treatment (±12 hours), in combination with one of the following: A neurological deterioration of ≥4 points on the National Institute of Health Stroke Scale (NIHSS; ranging from 0 - 42 with higher values indication more severe neurological deficit) from baseline, or from the lowest NIHSS value between baseline and 24 hours; persistent coma; or Death.

    Time frame: Within 24 hours (+/- 12 hours) after randomization

  2. Safety: Serious Adverse Events

    Time frame: Within 90 days after randomization

  3. Safety: Mortality

    All-cause mortality

    Time frame: Within 90 days after randomization

08

Study locations

1 of 2 sites recruiting
  • Klinik für Neurologie, Universitätsklinik der Paracelsus
    Nuremberg, 90471, Germany
    Recruiting
    • Jan Liman, Dr · ContactJan.Liman@klinikum-nuernberg.de · +49 (0) 911 398-2491
    • Jan Liman, Dr · Principal investigator
    • Markus Holtmannspötter, Dr · Principal investigator
  • University Hospital Basel
    Basel, 4031, Switzerland
    Not yet recruiting
    • Alex Brehm, PhD · Contactalex.brehm@usb.ch · +41 61 328 79 48
    • Marios Psychogios, Dr · Principal investigator
09

References and documents

Publications

  • Psychogios MN, Behme D, Schregel K, Tsogkas I, Maier IL, Leyhe JR, Zapf A, Tran J, Bahr M, Liman J, Knauth M. One-Stop Management of Acute Stroke Patients: Minimizing Door-to-Reperfusion Times. Stroke. 2017 Nov;48(11):3152-3155. doi: 10.1161/STROKEAHA.117.018077. Epub 2017 Oct 10. PubMed 29018132 ↗
  • Psychogios MN, Maier IL, Tsogkas I, Hesse AC, Brehm A, Behme D, Schnieder M, Schregel K, Papageorgiou I, Liebeskind DS, Goyal M, Bahr M, Knauth M, Liman J. One-Stop Management of 230 Consecutive Acute Stroke Patients: Report of Procedural Times and Clinical Outcome. J Clin Med. 2019 Dec 11;8(12):2185. doi: 10.3390/jcm8122185. PubMed 31835763 ↗

Individual participant data

Plan to share: Yes — All IPD collected throughout the trial

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Beginning 3 years after publication of the main results with no end date.

Access criteria: A proposal that describes the planned analyses shall be submitted to the sponsor-investigator of the trial.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.

Of 75 non-industry interventional studies with no phase under Hemorrhagic Stroke, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 31 months is below that.

Counting every sponsor, half of 89 studies reached it within 36 months; a quarter within 14 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 4, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Aug 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07052045
Lead sponsor
Prof. Dr. Jan Liman
Collaborators
University Hospital, Basel, Switzerland, Deutsche Forschungegemeinschaft, Klinikum Nürnberg
Responsible party
Prof. Dr. Jan Liman (Prof. Dr., Paracelsus Medical University) — Sponsor-investigator
First posted
Jul 4, 2025
Start date
Dec 2, 2025
Primary completion
Aug 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Jan 20, 2026

Study contacts

Alex Brehm, PhD
Contact
alex.brehm@usb.ch
+41 61 328 79 48
Jan Liman, Dr
principal investigator · Klinkum Nuremberg
Marios Psychogios, Dr.
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion